Keyphrases
Damaging Effects
74%
Divergent Effects
74%
Mitochondrial Dysfunction
74%
Survival Chances
74%
HIV-1 Reverse Transcriptase
74%
Rilpivirine
74%
Methylglyoxal
74%
Oxidative Stress
74%
Pancreatic β-cell Function
74%
Efavirenz
62%
Type 2 Diabetes Mellitus (T2DM)
62%
Hepatic Complications
50%
Hepatic Disease
50%
Diabetic
50%
Hyperglycemia
50%
Nucleosides
37%
INS-1E Cells
37%
Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)
37%
Reverse Transcriptase Inhibitors
37%
Doravirine
24%
Tenofovir Disoproxil Fumarate
24%
Emtricitabine
24%
Insulin
24%
β-Cell Survival
24%
β-cell Function
24%
Cell Viability
24%
Type 2 Diabetic
24%
Therapeutic Adjuvant
24%
Type 2 Diabetes Complications
24%
Physiological Model
24%
Osmotic Stress
24%
Underlying Pathology
24%
Incomplete Knowledge
24%
Adjuvant Therapy
24%
Diabetes Incidence
24%
Hepatocytes
24%
Renal System
24%
Diabetes Complications
24%
University of Brighton
24%
Dicarbonyl Stress
24%
Glucose Metabolite
24%
Intracellular Concentration
24%
Hepatocyte Function
24%
Vascular System
24%
World Population
24%
Clinical Application
24%
Glucose-regulated Protein 78 (GRP78)
12%
Oxidative Stress Toxicity
12%
Apoptosis-necrosis
12%
Type 2 Diabetes Mellitus Risk
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Diabetes Mellitus
74%
Rilpivirine
74%
RNA Directed DNA Polymerase Inhibitor
74%
RNA Directed DNA Polymerase
74%
Methylglyoxal
74%
Efavirenz
62%
Hyperglycemia
50%
Liver Disease
50%
Nonnucleoside Reverse Transcriptase Inhibitor
37%
Nucleoside
37%
Doravirine
24%
Tenofovir Disoproxil
24%
Cell Viability
24%
Emtricitabine
24%
HIV
24%
Adjuvant
24%
Diabetic Complication
24%
Mitochondrial Toxicity
12%
Necrosis
12%
Adenosine Triphosphate
12%
Synthetase
12%
Insulinoma
12%
Messenger RNA
12%
Medicine and Dentistry
Methylglyoxal
74%
Mitochondrial Disorder
74%
Maturity Onset Diabetes of the Young
50%
Diabetes Mellitus
50%
Hyperglycemia
50%
Liver Disease
50%
Metabolite
50%
Adjuvant
24%
Osmotic Stress
24%
Renal System
24%
Liver Function
24%
Vascular System
24%
In Vitro
24%
Mediator
24%
Complications of Diabetes Mellitus
24%
Diabetes
24%
Adjuvant Therapy
24%
Hepatocyte
24%